Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04220866
Title Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

head and neck squamous cell carcinoma

Therapies

Pembrolizumab + Ulevostinag

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | AUT

Facility Status City State Zip Country Details
UCLA Hematology & Oncology ( Site 0005) Los Angeles California 90095 United States Details
University of California at San Francisco ( Site 0006) San Francisco California 94158 United States Details
Henry Ford Hospital ( Site 0012) Detroit Michigan 48202 United States Details
Washington University ( Site 0021) Saint Louis Missouri 63110 United States Details
Sanford Cancer Center Oncology Clinic ( Site 0014) Sioux Falls South Dakota 57104 United States Details
Huntsman Cancer Institute ( Site 0004) Salt Lake City Utah 84112 United States Details
Chris OBrien Lifehouse ( Site 0040) Camperdown New South Wales 2050 Australia Details
Calvary Central Districts Hospital ( Site 0042) Elizabeth Vale South Australia 5112 Australia Details
Monash Health-Monash Medical Centre ( Site 0041) Clayton Victoria 3168 Australia Details
Ordensklinikum Linz Gmbh - Barmherzige Schwestern ( Site 0051) Linz Oberosterreich 4010 Austria Details
Allgemeines Krankenhaus der Stadt Wien ( Site 0049) Vienna/Wien Wien 1090 Austria Details
SCRI-CCCIT GesmbH ( Site 0050) Salzburg 5020 Austria Details
Centro Regional Integrado de Oncologia ( Site 0062) Fortaleza Ceara 60336-232 Brazil Details
Hospital de Caridade de Ijui ( Site 0061) Ijui Rio Grande Do Sul 98700-000 Brazil Details
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0058) Sao Paulo 01246-000 Brazil Details
Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0064) Sao Paulo 01321-001 Brazil Details
Centre Antoine Lacassagne ( Site 0070) Nice Alpes-Maritimes 06189 France Details
Centre Leon Berard ( Site 0072) Lyon Auvergne 69373 France Details
IUCT - Oncopole ( Site 0069) Toulouse Haute-Garonne 31059 France Details
Centre Oscar Lambret ( Site 0071) Lille Nord 59000 France Details
Gustave Roussy ( Site 0068) Villejuif Val-de-Marne 94800 France Details
Chaim Sheba Medical Center ( Site 0076) Ramat Gan Tel Aviv 5265601 Israel Details
Rambam Medical Center ( Site 0077) Haifa 3109601 Israel Details
Hadassah Medical Center. Ein Kerem ( Site 0078) Jerusalem 9112001 Israel Details
Severance Hospital ( Site 0103) Seoul 03722 Korea, Republic of Details
Asan Medical Center ( Site 0104) Seoul 05505 Korea, Republic of Details
Haukeland Universitetssykehus, Klinisk forskningspost voksne ( Site 0086) Bergen Hordaland 5021 Norway Details
Oslo Universitetssykehus Radiumhospitalet ( Site 0085) Oslo 0379 Norway Details
H.U. Vall de Hebron ( Site 0112) Barcelona 08035 Spain Details
Hospital Clinico de Barcelona ( Site 0116) Barcelona 08036 Spain Details
Hospital Universitario Ramon y Cajal ( Site 0115) Madrid 28034 Spain Details
Hospital Universitario Virgen de la Victoria ( Site 0114) Malaga 29010 Spain Details
Royal Marsden NHS Foundation Trust ( Site 0031) London London, City Of SW3 6JJ United Kingdom Details
Royal Marsden Hospital Sutton-Surrey ( Site 0032) Sutton Surrey SM2 5PT United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field